Human Growth Hormone

Human Growth Hormone Market Outlook

The global Human Growth Hormone (HGH) market is projected to reach approximately USD 5.9 billion by 2035, growing at a compound annual growth rate (CAGR) of around 7.5% during the forecast period of 2025 to 2035. This robust growth can be attributed to several factors, including the rising prevalence of growth hormone deficiencies among children and adults, increasing awareness regarding the benefits of HGH therapy, and advancements in healthcare infrastructure. Additionally, the surge in sports and fitness applications, coupled with the emergence of innovative delivery methods, further propels the market growth. The growing geriatric population, who are more susceptible to hormonal imbalances, also plays a significant role in driving the demand for HGH products.

Growth Factor of the Market

The Human Growth Hormone market is predominantly influenced by factors such as the burgeoning awareness about HGH therapy and its corresponding health benefits. The increasing diagnosis rates of growth hormone deficiencies in children and adults have catalyzed market growth, as healthcare professionals are more inclined to prescribe HGH therapy to address these conditions. Furthermore, the evolution of delivery methods, including injectables and sprays, has made HGH therapy more accessible, encouraging patients to seek treatment. Additionally, the uptick in lifestyle-related issues has led to a growing interest in anti-aging therapies, further amplifying the demand for HGH products. Moreover, significant investments in research and development by pharmaceutical companies are expected to accelerate product innovation and diversify the HGH market, making it an attractive segment for stakeholders.

Key Highlights of the Market

• Projected global market size of approximately USD 5.9 billion by 2035, with a CAGR of 7.5%.
• Increased prevalence of growth hormone deficiencies driving demand across various demographics.
• Innovative delivery methods such as sprays and injectables enhancing treatment accessibility.
• Growing interest in anti-aging therapies among the geriatric population.
• Significant R&D investments leading to product innovation and market diversification.

By Product Type

Powder:

The powder segment of the Human Growth Hormone market is notable for its long shelf life and ease of storage, making it a preferred choice among both healthcare providers and patients. Typically reconstituted with a diluent just before administration, powdered HGH is highly effective in delivering targeted results for individuals suffering from growth hormone deficiencies. The increased adoption of powdered formulations can be attributed to their cost-effectiveness, particularly in clinical settings where multiple doses are required. Additionally, advancements in formulation technology have led to improved stability and efficacy, further enhancing the segment's appeal.

Liquid:

Liquid formulations of Human Growth Hormone are gaining traction due to their ready-to-use nature, which eliminates the need for reconstitution and provides convenience for patients. These formulations often come in pre-filled syringes or vials, making administration straightforward and reducing the potential for dosing errors. Liquid HGH products are particularly popular among pediatric patients and those who may require assistance with injections, as they offer a more user-friendly alternative. The liquid segment is expected to contribute significantly to market growth, driven by the increasing preference for ease of use and the enhanced patient experience.

Tablet:

The tablet form of Human Growth Hormone represents a niche but growing segment within the market. While not as commonly prescribed as injectable forms, tablets provide an alternative for patients who may be hesitant or unable to administer injections. The convenience of oral ingestion can encourage adherence to treatment regimens, especially among those who prioritize non-invasive options. Ongoing research into the bioavailability of oral HGH formulations is expected to catalyze growth in this segment, as improved absorption technologies emerge, potentially transforming patient experiences with HGH therapy.

Spray:

HGH sprays are an innovative delivery method gaining popularity due to their ease of use and non-invasive nature. These formulations offer a patient-friendly alternative to traditional injections, making them particularly attractive to individuals reluctant to use needles. The rapid absorption of HGH through mucosal membranes allows for quick bioavailability, which can enhance therapeutic outcomes. As the demand for convenient and effective delivery systems continues to rise, the HGH spray segment is expected to grow, driven by both patient preference and ongoing advancements in transdermal technology.

Injectable:

Injectables remain the dominant product type in the Human Growth Hormone market, accounting for a significant share due to their established efficacy and reliability. This method allows for precise dosing and effective absorption, making it the preferred choice for patients with growth hormone deficiencies. Injectable HGH is typically administered subcutaneously, and while it requires some level of skill for administration, many patients and healthcare providers favor this route due to its proven results. The ongoing development of innovative delivery devices, such as auto-injectors and pen devices, is anticipated to further enhance patient compliance and satisfaction in this segment.

By Application

Growth Hormone Deficiency:

The application of Human Growth Hormone for growth hormone deficiency (GHD) represents the largest segment of the market. GHD can occur in both children and adults, leading to stunted growth and other metabolic issues. The increasing diagnosis of GHD, coupled with heightened awareness among healthcare professionals, has propelled the demand for HGH therapy in this category. Treatment regimens typically involve lifelong administration of HGH to manage symptoms and improve overall health outcomes, thus ensuring sustained market growth in this application area.

Turner Syndrome:

Human Growth Hormone is often prescribed to patients with Turner Syndrome, a genetic disorder that affects development in females. The administration of HGH can significantly improve height outcomes and overall quality of life for affected individuals. As the understanding of Turner Syndrome and its impact on growth continues to evolve, the demand for HGH therapy in this application is likely to increase. Furthermore, ongoing research into the long-term benefits of HGH treatment for Turner Syndrome patients may lead to expanding clinical guidelines and enhanced therapeutic approaches.

Prader-Willi Syndrome:

Prader-Willi Syndrome (PWS) is another critical application area for Human Growth Hormone therapy. Individuals with PWS often exhibit growth hormone deficiencies, contributing to obesity and related health issues. HGH therapy can aid in managing body composition and promoting lean body mass, thereby enhancing the overall health of patients with this syndrome. The growing awareness of PWS and the importance of early intervention with HGH is expected to boost market growth, especially as healthcare providers seek to improve patient outcomes through targeted therapies.

Short Bowel Syndrome:

Short Bowel Syndrome (SBS) is a serious condition where the body cannot absorb enough nutrients due to a significant reduction in the functional length of the small intestine. HGH therapy has been found to improve nutrient absorption and growth in patients with SBS, making it a critical application area. The rising incidence of SBS due to surgical interventions or congenital defects has led to increased prescriptions of HGH in this population. Ongoing clinical studies examining the efficacy of HGH in managing SBS are likely to validate its use, promoting further growth in this segment.

Idiopathic Short Stature:

Idiopathic Short Stature (ISS) refers to significantly short stature in children without any identifiable cause. HGH therapy has shown promising results in improving height in children diagnosed with ISS, capturing the attention of parents and healthcare professionals alike. The growing trend toward early intervention for height-related concerns is likely to drive demand for HGH products in this application. As more pediatricians become informed about the benefits of HGH treatment for ISS, it is anticipated that this application will see sustained growth, contributing to the overall expansion of the HGH market.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a vital role in the distribution of Human Growth Hormone products, particularly for patients requiring specialized care. These pharmacies often have direct access to healthcare providers and patients, allowing for seamless prescription fulfillment and patient counseling. The environment within hospital pharmacies tends to facilitate better monitoring and management of patients undergoing HGH therapy, ensuring that dosing regimens are adhered to and any side effects are promptly addressed. As the number of hospitals and healthcare facilities continues to grow, the significance of hospital pharmacies in the HGH market is expected to expand.

Retail Pharmacies:

Retail pharmacies serve as a common distribution channel for patients seeking Human Growth Hormone therapy, providing accessibility and convenience. These pharmacies cater to a broader patient demographic, including those who might not be receiving continuous care from a healthcare provider. By partnering with local healthcare professionals, retail pharmacies can offer education and support regarding HGH therapy, thereby enhancing patient compliance. The ongoing trend of healthcare consumerization, where patients seek more control over their treatment pathways, is likely to further solidify the role of retail pharmacies in the HGH market.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for Human Growth Hormone products, particularly in the wake of the COVID-19 pandemic, which accelerated the adoption of digital health solutions. The convenience of online ordering, coupled with discreet delivery, appeals to patients who may feel hesitant about seeking HGH therapy in traditional settings. Online pharmacies provide a platform for patients to compare products, read reviews, and access educational resources about HGH therapy. Despite regulatory challenges, the growth of telehealth services and remote consultations is expected to further enhance the role of online pharmacies in the HGH market.

Specialty Clinics:

Specialty clinics focusing on endocrinology and hormone therapies are crucial distribution points for Human Growth Hormone. These clinics often provide comprehensive assessments and individualized treatment plans tailored to each patient's needs. The specialized knowledge of healthcare providers within these clinics enables them to address complex cases of growth hormone deficiencies effectively. As patients increasingly seek expert care for hormonal issues, the prominence of specialty clinics in the HGH market is anticipated to rise, leading to improved patient outcomes and higher treatment adherence.

Drug Stores:

Drug stores serve as an important distribution channel for Human Growth Hormone, catering to patients who require easy access to their medications. These establishments often stock a variety of HGH products, catering to the diverse needs of patients. The convenience of drug stores, combined with a focus on customer service, allows for meaningful interaction between pharmacists and patients, enabling discussions about proper medication use and potential side effects. As the trend of personalized medicine continues to grow, drug stores are expected to play an increasingly vital role in the distribution of HGH products, ensuring accessibility for all patients seeking therapy.

By Ingredient Type

Somatropin:

Somatropin is the most widely used ingredient in Human Growth Hormone products, effectively mimicking natural growth hormone produced by the pituitary gland. Its use spans various applications, including treatment for growth hormone deficiencies in both children and adults. The growing acceptance of somatropin for off-label uses, such as anti-aging and athletic performance enhancement, has also contributed to its dominance in the market. As healthcare professionals continue to recognize the therapeutic benefits of somatropin, its market share is expected to remain robust, bolstered by ongoing research into its efficacy in various clinical scenarios.

Somatrem:

Somatrem serves as a slightly different formulation of Human Growth Hormone, with an additional methionine at the N-terminus, which provides unique properties and efficacy. While it is used less frequently than somatropin, somatrem has its niche in the market, particularly for specific medical indications. Its distinct profile may present advantages in certain patient populations, including those who have specific growth disorders. As healthcare providers continue to explore different formulations and their implications for treatment, somatrem may see increased interest and use within specialized clinical settings.

Mecasermin:

Mecasermin is a recombinant form of insulin-like growth factor-1 (IGF-1), primarily utilized in patients who exhibit severe growth hormone resistance. Its unique mechanism of action makes it particularly beneficial for patients with specific conditions such as growth hormone receptor deficiencies. The expanding body of clinical evidence supporting the efficacy of mecasermin in addressing growth-related issues is anticipated to enhance its market presence. As healthcare providers become more aware of the benefits of this ingredient, it is likely to play a more prominent role in the overall Human Growth Hormone market.

Somapacitan:

Somapacitan is an innovative long-acting growth hormone therapy that offers once-weekly dosing, providing an alternative for patients who may struggle with daily injections. This characteristic has the potential to significantly improve patient adherence to treatment regimens, addressing one of the major challenges associated with traditional HGH therapies. The favorable pharmacokinetic profile of somapacitan is expected to garner attention from both healthcare providers and patients, leading to an increase in its market share as more individuals seek convenient and effective treatment options.

Somavaratan:

Somavaratan is another long-acting growth hormone product in development, designed to offer an alternative to existing therapies. Its potential to provide sustained growth hormone action with less frequent dosing could revolutionize the way growth hormone deficiencies are managed in clinical practice. As research and development initiatives progress, somavaratan may emerge as a highly desired option for patients and healthcare professionals alike. The ongoing exploration of its applications and benefits is anticipated to drive increased interest and adoption in the Human Growth Hormone market.

By Region

The Human Growth Hormone market exhibits significant regional disparities, with North America being the largest market, accounting for approximately 40% of the total market share. This dominance can be attributed to the high prevalence of growth hormone deficiencies, extensive healthcare infrastructure, and a favorable reimbursement landscape for HGH therapies. The North American market is expected to grow at a CAGR of 6.8% over the forecast period, driven by rising awareness of hormone replacement therapies and the growing number of diagnostic laboratories specializing in hormonal disorders. Additionally, the increasing number of clinical studies investigating the potential benefits of HGH across various demographics supports market growth in this region.

In Europe, the Human Growth Hormone market is also witnessing significant growth, anticipated to reach USD 2 billion by 2035, driven by a combination of factors including increasing healthcare expenditures, a growing geriatric population, and heightened awareness regarding growth hormone therapies. The European market benefits from robust regulatory frameworks encouraging the use of HGH for various indications. Additionally, advancements in the pharmaceutical industry and increasing investments in R&D are expected to propel innovation, resulting in a wider variety of HGH products. Emerging markets in Asia Pacific and Latin America are also poised for growth as awareness of growth hormone therapies improves, coupled with rising healthcare standards.

Opportunities

The Human Growth Hormone market is poised for substantial opportunities, particularly due to the increasing awareness of hormone-related health issues and the corresponding growth therapy. As demographics shift, particularly with an aging population, the demand for anti-aging treatments and growth hormone therapies is expected to rise. This presents a significant opportunity for pharmaceutical companies to develop innovative formulations and delivery methods that cater to the specific needs of older adults. Additionally, with the growth of telemedicine and digital health solutions, there is potential for expanding access to HGH therapies, enabling patients to receive care without the barriers of traditional healthcare systems.

Furthermore, the expansion of research into the long-term effects of HGH therapy opens new avenues for applications beyond traditional uses, such as its role in enhancing athletic performance and its potential benefits in metabolic disorders. The growing trend of personalized medicine, where treatments are tailored to individual patient profiles, also offers an opportunity for HGH products to be developed and marketed more effectively. As healthcare systems increasingly adopt value-based care models, demonstrating the efficacy and cost-effectiveness of HGH therapy can provide a competitive advantage, making it an appealing option for stakeholders in the healthcare landscape.

Threats

One significant threat to the Human Growth Hormone market is the rising concern regarding misuse and abuse of HGH, particularly in sports and bodybuilding communities. The perception of HGH as a performance-enhancing substance has led to increased scrutiny and regulation, which may limit its availability and impact market growth. Moreover, potential side effects associated with HGH therapy, such as acromegaly and insulin resistance, can deter patients and healthcare providers from utilizing these therapies. Regulatory hurdles, including stringent approval processes and monitoring requirements, may also pose challenges for companies seeking to introduce new HGH products into the market.

Another potential restraining factor is the high cost associated with HGH therapy, which may make it less accessible to a significant portion of the population. Patients without adequate insurance coverage may find it challenging to afford such treatments, leading to lower adoption rates. Additionally, the presence of alternative therapies for growth deficiencies, including lifestyle interventions and other hormonal treatments, may further limit the market potential for HGH products. As competition increases and more players enter the market, price pressure may become a significant concern, potentially impacting profitability for companies within the HGH sector.

Competitor Outlook

• Genentech, Inc.
• Merck KGaA
• Pfizer Inc.
• AbbVie Inc.
• Novartis AG
• Ferring Pharmaceuticals
• Ipsen S.A.
• Teva Pharmaceutical Industries Ltd.
• Roche Holding AG
• Helsinn Healthcare SA
• Sandoz International GmbH
• Eli Lilly and Company
• Boehringer Ingelheim
• Amgen Inc.
• Hikma Pharmaceuticals PLC

The competitive landscape of the Human Growth Hormone market is characterized by the presence of several key players, each striving to enhance their product offerings and expand their market reach. Major pharmaceutical companies, such as Genentech and Pfizer, dominate the market with their well-established HGH products, leveraging extensive research and development capabilities to introduce innovative therapies. As competition intensifies, companies are increasingly focusing on strategic collaborations, mergers, and acquisitions to strengthen their market position and diversify their product portfolios. Additionally, investments in R&D and the development of long-acting formulations are essential strategies employed by competitors to differentiate themselves in this dynamic market.

Genentech, a part of the Roche Group, is a leading player in the HGH market, well-known for its flagship product, Nutropin. The company continues to invest in research to explore new applications for growth hormone therapy across various demographics. Similarly, Pfizer has established a strong presence with its Genotropin product, targeting both pediatric and adult populations. Pfizer's ongoing commitment to advancing its HGH portfolio through innovative formulations positions it as a formidable competitor in the market.

Merck KGaA and AbbVie are also notable players, focusing on expanding their product lines and enhancing patient accessibility to HGH therapies. Merck KGaA’s Saizen has garnered considerable attention for its efficacy, while AbbVie has made strides with its product, Humatrope, which continues to be a mainstay in HGH therapy. Both companies prioritize safety and efficacy in their product development processes, ensuring that they meet evolving patient needs while navigating complex regulatory landscapes. As the Human Growth Hormone market continues to evolve, these companies are likely to play a crucial role in shaping its future trajectory.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Ipsen S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Genentech, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Helsinn Healthcare SA
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Ferring Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hikma Pharmaceuticals PLC
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sandoz International GmbH
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Human Growth Hormone Market, By Application
    • 6.1.1 Growth Hormone Deficiency
    • 6.1.2 Turner Syndrome
    • 6.1.3 Prader-Willi Syndrome
    • 6.1.4 Short Bowel Syndrome
    • 6.1.5 Idiopathic Short Stature
  • 6.2 Human Growth Hormone Market, By Product Type
    • 6.2.1 Powder
    • 6.2.2 Liquid
    • 6.2.3 Tablet
    • 6.2.4 Spray
    • 6.2.5 Injectable
  • 6.3 Human Growth Hormone Market, By Ingredient Type
    • 6.3.1 Somatropin
    • 6.3.2 Somatrem
    • 6.3.3 Mecasermin
    • 6.3.4 Somapacitan
    • 6.3.5 Somavaratan
  • 6.4 Human Growth Hormone Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Drug Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Human Growth Hormone Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Human Growth Hormone market is categorized based on

By Product Type

• Powder
• Liquid
• Tablet
• Spray
• Injectable

By Application

• Growth Hormone Deficiency
• Turner Syndrome
• Prader-Willi Syndrome
• Short Bowel Syndrome
• Idiopathic Short Stature

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Drug Stores

By Ingredient Type

• Somatropin
• Somatrem
• Mecasermin
• Somapacitan
• Somavaratan

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Genentech, Inc.
• Merck KGaA
• Pfizer Inc.
• AbbVie Inc.
• Novartis AG
• Ferring Pharmaceuticals
• Ipsen S.A.
• Teva Pharmaceutical Industries Ltd.
• Roche Holding AG
• Helsinn Healthcare SA
• Sandoz International GmbH
• Eli Lilly and Company
• Boehringer Ingelheim
• Amgen Inc.
• Hikma Pharmaceuticals PLC